Clovis Oncology, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q4 2011 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Clovis Oncology, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2011 to Q3 2022.
  • Clovis Oncology, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2022 was $35K, a 169% increase year-over-year.
  • Clovis Oncology, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2022 was -$406K, a 26% increase year-over-year.
  • Clovis Oncology, Inc. annual Income Tax Expense (Benefit) for 2021 was -$404K, a 26.1% increase from 2020.
  • Clovis Oncology, Inc. annual Income Tax Expense (Benefit) for 2020 was -$547K, a 130% decline from 2019.
  • Clovis Oncology, Inc. annual Income Tax Expense (Benefit) for 2019 was $1.8M, a 196% increase from 2018.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$406K $35K +$22K +169% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 -$428K -$41K -$38K -1267% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-08
Q1 2022 -$390K -$120K +$14K +10.4% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 -$404K -$280K +$145K +34.1% Oct 1, 2021 Dec 31, 2021 10-K 2022-02-24
Q3 2021 -$549K $13K +$31K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$580K -$3K +$33K +91.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$613K -$134K -$66K -97.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$547K -$425K -$2.91M -117% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $2.36M -$18K +$332K +94.9% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-24
Q2 2020 $2.03M -$36K +$140K +79.5% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-24
Q1 2020 $1.89M -$68K +$92K +57.5% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-24
Q4 2019 $1.8M $2.48M +$1.6M +180% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $202K -$350K -$363K -2792% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 $565K -$176K -$143K -433% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 $708K -$160K +$100K +38.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 $608K $888K +$1.87M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$1.26M $13K +$1.25M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$2.51M -$33K +$1.25M +97.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$3.76M -$260K -$177K -213% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$3.58M -$980K -$2.41M -168% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$1.17M -$1.23M -$1.01M -444% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$158K -$1.28M +$27.8M +95.6% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$27.9M -$83K +$4.1M +98% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$32M $1.43M +$30M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-27
Q3 2016 -$62M -$227K +$401K +63.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-27
Q2 2016 -$62.4M -$29.1M -$29.1M -161539% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-27
Q1 2016 -$33.4M -$4.18M -$4.28M -4199% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-27
Q4 2015 -$29.1M -$28.6M -$28.4M -15683% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 -$689K -$628K -$920K -315% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 $231K $18K -$50K -73.5% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 $281K $102K -$2.03M -95.2% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 $2.31M -$181K -$233K -448% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 $2.54M $292K Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 $68K Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 $2.13M Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q4 2013 $52K Oct 1, 2013 Dec 31, 2013 10-K 2015-02-27
Q2 2012 -$35K Apr 1, 2012 Jun 30, 2012 10-K 2014-02-28
Q1 2012 $8K Jan 1, 2012 Mar 31, 2012 10-K 2014-02-28
Q4 2011 $27K Oct 1, 2011 Dec 31, 2011 10-K 2013-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.